Case Studies

Biologics Consulting: Antibodies to Treat Bacterial Infections An established US biotech company with $bn sales was looking for a team of expert antibody consultants to help them understand the...

Alacrita's radiopharmaceuticals consultant has had a distinguished career in the nuclear medicine industry. For a recent radiopharmaceuticals strategy project for a major public/private investor in a...

Valuations For a biotech company engaged in licensing discussions with a number of major pharmaceutical companies, Alacrita developed rNPV valuations for each program. This 'theoretical' valuation...

Due diligence For a financial investor, Alacrita conducted an IP assessment on a late stage cell therapy investment opportunity. The assessment revealed that the US and EPO patents relied on just...

Challenge: A leading cancer research charity needed project management and drug development expertise to shepherd two preclinical programs into Phase I/II clinical trials. Alacrita was engaged to...

Target Assessment and intellectual property For a mid-cap pharmaceutical company seeking to establish a biologics pipeline through partnership with a mAb development boutique, Alacrita assessed the...

Background Alacrita`s client was nearing the completion of a pivotal Phase III with a novel antibody-based therapeutic. The product was designed to delay recurrence in cancer patients with minimum...

Challenge: After a seed investment, a startup biotech had built an IP portfolio in the field of glucosinolates, chemicals found in brassica vegetables, that are potent inducers of cytoprotective...

Alacrita is a leading provider of due diligence to the pharmaceutical industry. Its core team of partners, each of whom has industry experience, are supported by a team of expert, life science...